© Reuters. FILE PHOTO: The Regeneron Pharmaceuticals company logo is seen on a building at the company’s Westchester campus in Tarrytown, New York, U.S. September 17, 2020. REUTERS/Brendan McDermid/File Photo
(Reuters) – Regeneron Pharmaceuticals Inc (NASDAQ:) reported an about 46% plunge in its fourth-quarter profit on Friday, hurt by a drop in U.S. sales of its blockbuster eye drug, Eylea, and drying up of its COVID-19 antibody cocktail sales.
The company reported net income of $1.20 billion, or $10.50 per share, in the quarter ended Dec. 31, compared with $2.23 billion, or $19.69 per share, a year earlier.
(This story has been corrected to fix year-ago net income per share to $19.69 from $23.42 in paragraph 2)